Specifically, CDKN2A promoter methylation has been observed in thymomas and thymic carcinomas, presumably leading to the inactivation of the p16/RB axis [71], while higher levels of MTHFR methylation were observed in MG-associated TETs [72]. Here, CDKN2A is linked to myasthenia gravis.